Effectiveness of oral clonidine and gabapentin on peripheral neuropathy in diabetic patients in southwestern Iran: a randomized clinical trial

BMC Endocrine Disorders

Research

Sajad Hassanzadeh¹  Soraya Bagheri¹  Seyed Majid Ahmadi¹  Isaac Moradishibany¹  Hosein Dolatkhah¹  Sajjad Reisi²  Seyed Ahmadreza Ahmadi³ 

[1] Department of Internal Medicine, School of Medicine, Yasuj University of Medical Sciences, Yasuj, Iran;Genetic and Environmental Adventures Research Center, School of Abarkouh Paramedicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran;School of Medicine, Jundishahpour University of Medical Sciences, Ahvaz, Iran;

关键词: Clonidine;    Gabapentin;    Peripheral neuropathy;    Diabetes;    Neuropathic pain;    Severity of neuropathic pain;   

DOI  :  10.1186/s12902-023-01486-0

 received in 2023-04-14, accepted in 2023-10-11,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundPeripheral neuropathy is not only the most prevalent consequence of diabetes but also the main reason for foot ulceration, disability, and amputation. Therefore, the current study aims to determine the effectiveness of oral clonidine and gabapentin on peripheral neuropathy in diabetic patients.MethodsThis 12-week, randomized, and parallel-group trial was conducted to compare the efficacy of oral clonidine and gabapentin with gabapentin alone in diabetic patients in southwest Iran during the first half of 2021. Thirty patients with type 2 diabetes with peripheral neuropathy as assessed by a visual analog scale (VAS) and divided into two groups of 15 patients, treated for up to three months. The data were analyzed using SPSS-21 software. In order to report the results, descriptive indices, independent t-test, one-way analysis of covariance (ANCOVA) and analysis of variance with repeated measures were used.ResultsThe mean and standard deviation of the age of the participants in the clonidine + gabapentin group was equal to 50.20 ± 7.44, and in the gabapentin group was equal to 50.47 ± 7.57 (t = 0.10, P-value = 0.923). This research showed a significant difference between the clonidine + gabapentin group and with gabapentin group in terms of neuropathic pain and the severity of neuropathic pain (P < 0.001).ConclusionsAccording to this research results, clonidine + gabapentin can reduce neuropathic pain and the severity of neuropathic pain in diabetic patients. Therefore, it is recommended that healthcare professionals with diabetes expertise prescribe these medications to reduce neuropathic pain and its severity.Trial registrationThis study was registered in the Iranian Clinical Trials System with the ID (IRCT20211106052983N1) on 14/01/2022.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 2